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doi:10.1016/j.kjms.2011.03.009Abstract The aim of this study was to evaluate the correlation among various preoperative
clinical variables, including certain prostate needle biopsy parameters, biochemical failure,
and adverse pathology, after radical retropubic prostatectomy (RRP). We retrospectively eval-
uated the records of our 156 patients who underwent RRP because of localized prostate
cancer. Serum prostate-specific antigen level, clinical stage, and the information obtained
from biopsy [Gleason score, number of positive cores, percentage of positive cores (PPCs) from
the dominant side of prostate, and overall PPC] were evaluated as predictors of adverse
pathology and biochemical failure. Of the patients, 30.2% (nZ 38) had nonorgan-confined
disease, 19.1% (nZ 24) had positive surgical margins, 11.9% (nZ 15) had positive seminal
vesicle invasion, and 16.7% (nZ 21) had biochemical failure after RRP. Multivariate analysis
demonstrated that a PPC value of 55% or more from the dominant side of prostate is the only
independent predictor of nonorgan-confined disease and seminal vesicle invasion. Clinical
stage (T2b), biopsy Gleason score, and PPC values of 55% or more from the dominant side of
prostate were found to be statistically significant predictors of positive surgical margin and
biochemical failure. Our results support that PPC from the dominant side of prostate is a useful
parameter for the prediction of adverse pathology and biochemical failure after RRP.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.gi, Numune Egitim ve Arastirma Hastanesi, Ulku Mah, Talatpasa Blv, Nr 5, Ankara 06100, Turkey.
ail.com (B.K. Aktas).
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Prostate cancer is the most frequently diagnosed neoplasia
in men older than 60 years and the second most common
cause of cancer deaths after lung cancer [1]. Given the high
success and low mortality rates, radical prostatectomy is
the most suitable treatment option for the patients who are
diagnosed with clinically localized prostate cancer and who
have a life expectancy of more than 10 years. Biochemical
failure-free survival rates were reported as 83% for 10 years
and 75% for 15 years after radical prostatectomy in patients
with localized prostate cancer [2].
Long-term prognosis after radical retropubic prostatec-
tomy (RRP) is closely related to pathological stage and
histological score of tumor [3,4]. Clinical stage, Gleason
score determined by biopsy, prostate-specific antigen
(PSA), and free/total PSA ratio are frequently used
parameters for the prediction of the pathological stages of
RRP candidates [5e7]. However, pathological examination
of RRP specimens usually reveals that almost 50% of
patients are understaged clinically [8]. Recently, contra-
dictory results were found by few studies investigating the
relationship among the prostate biopsy findings (such as
number of positive cores, percentage of positive cores
(PPCs), and cancer length in a positive biopsy core), post-
operative pathological stage, and biochemical failure
[9e11].
In this study, we evaluated the efficacy of prostate
biopsy parameters (number of positive cores, PPC from the
dominant side of prostate, and overall PPC) for the
prediction of adverse pathology (nonorgan-confined
diseases, positive surgical margins, and positive seminal
vesicle invasion) and biochemical failure after RRP.Materials and methods
One hundred fifty-six clinically localized prostate cancer
patients who underwent RRP between January 1997 and
May 2007 were included in our study. Clinical and patho-
logical data of patients were evaluated retrospectively.
The patients with a history of previous radiation therapy or
hormonal therapy (nZ 7), patients with less than six cores
in their prostate biopsy specimens (nZ 20), and patients
with insufficient clinical data (nZ 3) were excluded from
the study.
The remaining 126 patients underwent a standard eval-
uation before RRP, including a detailed medical history,
digital rectal examination, transrectal ultrasonography
(TRUS), serum PSA determination, routine blood tests, chest
X-ray, pelvic computed tomography, and a radioisotope bone
scan. TRUS was performed with a Hitachi EUB-420 (Hitachi
Medical Corp., Tokyo, Japan) device using a 6.5 MHz biplanar
transrectal probe. TRUS-guided prostate biopsy was per-
formed in patients with abnormal digital rectal examination
findings and/or high serum PSA levels (4 ng/mL). System-
atic prostatic biopsies using an 18-gauge needle and a spring-
loaded biopsy gun were obtained, including six or more
cores, with at least three from each side. Serum PSA levels
were measured by using monoclonal Tandem-R assay
(Hybritech Inc., San Diego, CA, USA).The PPC was calculated by dividing the number of
positive cores by the total number of biopsy cores and
multiplying the result by 100. Separate PPC values were
calculated for left and right halves and the whole gland.
The side of the prostate (left or right) with the greater PPCs
was considered as the dominant side and the opposite side
as the nondominant side.
The 1997 TNM staging system was used for clinical and
pathological staging [12]. Tumors were graded according
to the Gleason system [13]. Patients were examined every
3 months for the first year, every 6 months for the next 5
years, and annually thereafter. The mean follow-up period
was 23.6 20.1 months (range, 6e125 months).
Biochemical failure was defined as serum PSA levels of
0.2 ng/mL or higher on two consecutive analyses after
RRP.
The data were analyzed by statistical package for the
social sciences (SPSS Inc., Chicago, IL, USA) 11.5 package
program. Qualitative data were presented as the number
and the percentage of patients, whereas continuous vari-
ables were expressed as mean SD (standard deviation).
The optimal cutoff points for biopsy parameters to deter-
mine adverse pathology and biochemical failure were
evaluated by receiver operating characteristic analysis.
Area under curve and 95% confidence intervals were
calculated. The sensitivity, specificity, positive and nega-
tive predictive values, and the accuracy ratio of biopsy
parameters for detecting adverse pathology and biochem-
ical failure were calculated. Logistic regression analysis
was used in the evaluation of adverse pathology and Cox
Regression analysis were performed for biochemical failure
analysis. Odds ratio, relative risk, and 95% confidence
intervals for each independent variable were calculated. A
p value less than 0.05 were considered as statistically
significant.
Results
The mean age of patients was 62.1 6.1 years and the
mean serum PSA level was 11.3 9.02 ng/mL. Descriptive
data related to preoperative clinical and biopsy parameters
of the patients are shown in Table 1. The mean number of
positive cores PPC from the dominant side, and overall PPC
were 3.4 2.1, 50.2 26.3%, and 38.7 23.5%, respec-
tively. Postoperative pathologic descriptive features of
patients are shown in Table 2. Of the patients, 30.2%
(nZ 38) had nonorgan-confined disease, 19.1% (nZ 24)
had positive surgical margins, 11.9% (nZ 15) had positive
seminal vesicle invasion, and 16.7% (nZ 21) had biochem-
ical failure after RRP.
Determination of cutoff values for number of
positive cores, overall PPC, and dominant side for
prediction of unfavorable pathology and
biochemical failure
Receiver operating characteristic analysis revealed optimal
cutoff levels for dominant side and overall PPC and
number of positive cores as 55%, 40% and 4, respectively
(Table 2).
Table 1 Clinicopathological features of the patients
Characteristics Mean SD
Age (yr) 62.1 6.1
PSA (ng/mL) 11.3 9.02
Biopsy Gleason score 5.2 1.6
No. of cores 8.8 1.08
No. of positive cores 3.4 2.1
Overall PPC 38.7 23.5
PPC from the dominant side of prostate 50.2 26.3
Gleason score of RRP specimen 6.1 1.5
Clinicopathological features n (%)
Clinical stage
T1c 50 (39.7)
T2a 52 (41.3)
T2b 24 (19.1)
Pathological stage
T2a 41 (32.5)
T2b 47 (37.3)
T3a 23 (18.3)
T3b 15 (11.9)
Positive surgical margins 24 (19.1)
PPCZ percentage of positive cores; PSAZ prostate-specific
antigen; RRPZ radical retropubic prostatectomy; SDZ stan-
dard deviation.
Prognostic value of prostate biopsy parameters 309Calculation of predictive characteristics of the tests
for unfavorable pathology and biochemical failure
using the cutoff values of four or more for positive
cores, 40% or more for overall PPC, and 55% or
more for dominant-side PPC
The sensitivity, specificity, positive and negative predictive
values, and the accuracy ratios of four or more positiveTable 2 ROC analysis of biopsy parameters for adverse patholo
Parameters AUC
Nonorgan-confined disease
PPC from the dominant side of prostate 0.937
Overall PPC 0.853
No. of positive cores 0.842
Positive surgical margins
PPC from the dominant side of prostate 0.845
Overall PPC 0.821
No. of positive cores 0.788
Positive seminal vesicle invasion
PPC from the dominant side of prostate 0.912
Overall PPC 0.889
No. of positive cores 0.864
Biochemical failure
PPC from the dominant side of prostate 0.823
Overall PPC 0.843
No. of positive cores 0.791
AUCZ area under curve; CIZ confidence interval; PPCsZ percentagcores, 40% or more overall PPC, and 55% or more dominant
side PPC for the nonorgan-confined disease, positive
surgical margins, positive seminal vesicle invasion, and
biochemical failure were calculated and were shown in
Table 3. The sensitivity and specificity of biopsy parameters
for adverse pathology changed between 81.6e100 and
62e92.2, respectively, whereas the corresponding values
for biochemical failure were 70e85 and 62.1e74.2. The
sensitivity, specificity, positive and negative predictive
values, and accuracy ratio of 55% or more dominant-side
PPC for prediction of a nonorgan-confined disease were
higher than other potential predictors (Table 3).
Evaluation of risk factors for unfavorable pathology
In univariate analysis, clinical stage (T1c, T2b), biopsy
Gleason score, four or more positive biopsy cores, 55% or
more dominant-side PPC, and 40% or more overall PPC were
significant predictors of nonorgan-confined disease, posi-
tive surgical margins, and seminal vesicle invasion. Serum
PSA level was an additional predictor only for seminal
vesicle invasion (Table 4).
Multivariate analysis demonstrated that a 55% or more
dominant-side PPC significantly and independently predicts
a seminal vesicle invasion and a positive surgical margin.
Moreover, it is the only independent predictor of a non-
organ-confined disease. Besides a 55% or more dominant-
side PPC, a positive surgical margin was also predicted by
clinical stage, biopsy score, and an overall PPC value of 40%
or more (Table 5).
Evaluation of risk factors for biochemical failure
Clinical stage (T2b), biopsy Gleason score, four or more
positive cores 55% or more dominant-side PPC, and 40%
or more overall PPC predicted biochemical failure ingy and biochemical failure after radical prostatectomy
p 95% CIs for AUC
Lower limit Upper limit
<0.001 0.887 0.987
<0.001 0.784 0.923
<0.001 0.769 0.916
<0.001 0.753 0.938
<0.001 0.724 0.919
<0.001 0.692 0.883
<0.001 0.849 0.974
<0.001 0.824 0.954
<0.001 0.792 0.937
<0.001 0.735 0.910
<0.001 0.764 0.922
<0.001 0.703 0.879
e of positive cores; ROCZ receiver operating characteristic.
Table 3 Prediction of adverse pathology and biochemical failure after radical prostatectomy by using cutoff biopsy
parameters
Predictive parameter (cutoff) Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
PPC from the dominant side of prostate (55%)
Nonorgan confined disease 89.5 92.2 85.0 94.7 91.3
Positive surgical margins 83.3 78.0 50.0 94.7 79.2
Positive seminal vesicle invasion 93.3 74.0 35.0 98.7 76.5
Biochemical failure 70.0 72.6 35.0 92.0 72.2
Overall PPC (40%)
Nonorgan confined disease 73.7 82.3 66.7 86.7 79.5
Positive surgical margins 83.3 76.3 47.6 94.7 77.8
Positive seminal vesicle invasion 93.3 72.5 33.3 98.7 75.2
Biochemical failure 85.0 74.2 40.5 96.0 76.0
No. of positive cores (4)
Nonorgan confined disease 81.6 71.4 58.5 88.7 74.8
Positive surgical margins 83.3 63.7 37.7 93.5 67.8
Positive seminal vesicle invasion 100.0 62.0 28.3 100.0 66.9
Biochemical failure 85.0 62.1 32.1 95.2 66.1
NPVZ negative predictive value; PPCsZ percentage of positive cores; PPVZ positive predictive value.
Table 4 Univariate logistic regression analysis of factors predicting adverse pathology
Parameters OR p 95% CI for OR
Lower Upper
Nonorgan confined disease
PSA 1.03 0.237 0.98 1.07
Clinical stage (T1c) 1.00 0.022 d d
Clinical stage (T2a) 1.67 0.276 0.67 4.17
Clinical stage (T2b) 4.33 0.006 1.52 12.34
Biopsy Gleason score 1.26 0.066 0.98 1.61
PPC from the dominant side
of prostate 55%
100.58 <0.001 26.61 380.14
Overall PPC 40% 13.00 <0.001 5.16 32.77
No. of positive cores 4 11.07 <0.001 4.25 28.85
Positive surgical margins
PSA 1.03 0.141 0.99 1.08
Clinical stage (T1c) 1.00 0.020 d d
Clinical stage (T2a) 3.16 0.064 0.93 10.72
Clinical stage (T2b) 6.47 0.005 1.75 23.93
Biopsy Gleason score 1.76 <0.001 1.25 2.47
PPC from the dominant side
of prostate 55%
17.75 <0.001 5.44 57.92
Overall PPC 40% 16.14 <0.001 4.98 52.26
No. of positive cores 4 8.79 <0.001 2.77 27.91
Positive seminal vesicle invasion
PSA 1.06 0.035 1.00 1.11
Clinical stage (T1c) 1.00 0.006 d d
Clinical stage (T2a) 2.61 0.266 0.48 14.12
Clinical stage (T2b) 11.29 0.004 2.18 58.53
Biopsy Gleason score 1.56 0.019 1.07 2.26
PPC from the dominant side
of prostate 55%
39.85 <0.001 4.99 318.11
Overall PPC 40% 37.00 <0.001 4.65 294.64
No. of positive cores 4a d d d d
a There were no patients with both more than three positive cores and positive seminal vesicle invasion.
CIZ confidence interval; ORZ odds ratio; PPCZ percentage of positive cores; PSAZ prostate-specific antigen.
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Table 5 Multivariate logistic regression analysis of factors predicting adverse pathology after radical prostatectomy
Parameters OR p 95% CI for OR
Lower Upper
Nonorgan confined disease
PSA 1.06 0.263 0.96 1.18
Clinical stage (T1c) 0.215
Clinical stage (T2a) 0.35 0.298 0.05 2.50
Clinical stage (T2b) 2.74 0.333 0.36 21.18
Biopsy Gleason score 1.10 0.717 0.66 1.83
PPC from the dominant side
of prostate 55%
97.83 <0.001 15.09 634.18
Overall PPC 40% 2.28 0.383 0.36 14.64
No. of positive cores 4 1.53 0.703 0.17 13.52
Positive surgical margins
PSA 1.02 0.695 0.93 1.12
Clinical stage (T1c) 0.103
Clinical stage (T2a) 6.61 0.036 1.13 38.77
Clinical stage (T2b) 4.94 0.117 0.67 36.36
Biopsy Gleason score 2.25 0.002 1.35 3.77
PPC from the dominant side
of prostate 55%
6.03 0.042 0.90 40.58
Overall PPC 40% 19.53 0.018 1.67 228.32
No. of positive cores 4 0.27 0.307 0.02 3.36
Positive seminal vesicle invasion
PSA 1.10 0.111 0.98 1.23
Clinical stage (T1c) 0.214
Clinical stage (T2a) 1.81 0.598 0.20 16.42
Clinical stage (T2b) 5.71 0.112 0.67 48.81
Biopsy Gleason score 1.40 0.216 0.82 2.37
PPC from the dominant side
of prostate 55%
17.97 0.040 1.14 284.14
Overall PPC 40% 7.02 0.103 0.67 73.13
No. of positive cores 4a d d d d
a There were no patients both with more than three positive cores and with positive seminal vesicle invasion.
CIZ confidence interval; ORZ odds ratio; PPCZ percentage of positive cores; PSAZ prostate-specific antigen.
Prognostic value of prostate biopsy parameters 311univariate Cox regression analysis. In multivariate anal-
ysis, however, only clinical stage (T2b), biopsy Gleason
score, and 55% or more dominant-side PPC were found
to be independent predictors of biochemical failure
(Table 6).Discussion
Radical prostatectomy is considered as standard treatment
for localized prostate cancer. Limitations of RRP are mainly
because of locoregional tumor spread before surgery that is
difficult to detect and can lead to postoperative tumor
progression [14,15]. Gleason score, serum PSA level, and
clinical stage are main preoperative select parameters for
patients undergoing RRP [5e7]. Nevertheless, the number
of clinically understaged patients still remains high [6,16].
Recently, there has been an attempt to improve staging
accuracy before treatment by using the information
provided by prostate needle biopsies, such as the number
of cores with cancer, percentage of cancer positive cores,
and cancer length [9e11].Poulos et al. [17] showed that the number of positive
cores was a significant predictor of tumor volume in RRP
specimens. Wills et al. [18] determined that 89% of patients
who had Gleason scores of six or less, number of positive
cores two or less, and PSA levels lower than 4 ng/mL had
organ-confined disease. However, the number of positive
cores was not found to be a useful parameter for the
prediction of adverse pathology and biochemical failure
after RRP in various studies as it is in our study [9,10].
Recently, PPC in a prostate biopsy was thought to be
a significant predictor of an adverse pathology and
biochemical failure after RRP. D’Amico et al. [19] reported
that the patients with a PPC value of 50% or more consti-
tuted a high-risk group for biochemical failure after RRP.
Villamo´n-Fort et al. [9] reported that percentage of cancer
length in prostate biopsies was a more useful prognostic
factor than PPC in the prediction of pathological stage and
the risk of biochemical failure after RRP. They demon-
strated that the patients with a percentage of cancer
length of 24% or more, serum PSA level higher than
13 ng/mL, and/or Gleason score between 7 and 10 had
a high (>70%) biochemical failure rate.
Table 6 Cox regression analysis of factors predicting
biochemical failure after radical prostatectomy
Parameters RR p 95% CI for RR
Lower Upper
Univariate
PSA 1.02 0.262 0.99 1.05
Clinical stage (T1c) 1.00 0.063 d d
Clinical stage (T2a) 1.46 0.536 0.44 4.91
Clinical stage (T2b) 3.65 0.036 1.09 12.23
Biopsy Gleason score 1.57 0.008 1.13 2.20
PPC from dominant
side of prostate 55%
3.36 0.015 1.27 8.88
Overall PPC 40% 6.84 0.002 1.99 23.54
No. of positive cores
4
5.15 0.009 1.50 17.64
Multivariate
PSA 0.99 0.426 0.96 1.02
Clinical stage (T1c) d 0.050 d d
Clinical stage (T2a) 4.07 0.086 0.82 20.19
Clinical stage (T2b) 6.45 0.014 1.45 28.66
Biopsy Gleason score 1.61 0.019 1.08 2.39
PPC from dominant
side of prostate 55%
47.48 0.025 1.62 139.6
Overall PPC 40% 0.25 0.104 0.05 1.33
No. of positive
cores 4
0.29 0.428 0.01 6.13
CIZ confidence interval; PPCsZ percentage of positive cores;
PSAZ prostate-specific antigen; RRZ relative risk.
312 A. Memis et al.Clinical usage of percentage of cancer length is quite
limited because its determination requires extra time,
effort, and caution. However, Freedland et al. [20] inves-
tigated the clinical use of an easily determined parameter,
PPC from the dominant side of prostate for the prediction
of nonorgan-confined disease, and biochemical failure
after RRP. They reported that it is more efficient to use PPC
from the dominant side of prostate instead of overall PPC
for the prediction of biochemical failure after RRP. As it is
in our study, PPC from the dominant side of prostate is
a stronger independent factor than the number of positive
cores and overall PPC in the prediction of nonorgan-
confined disease and biochemical failure after RRP in that
study. Main limitations of our study are having a retro-
spective design and relatively shorter mean follow-up
period.
In conclusion, our results support that PPC from the
dominant side of prostate is a useful parameter for the
prediction of adverse pathology, particularly nonorgan-
confined disease, and biochemical failure after RRP. Our
data should be validated with prospective, larger trials with
longer follow-up durations.
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